losartan has been researched along with Labyrinth Diseases in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Labyrinth Diseases: Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer zum Gottesberge, AM | 1 |
| Massing, T | 1 |
| Sasse, A | 1 |
| Palma, S | 1 |
| Hansen, S | 1 |
1 other study available for losartan and Labyrinth Diseases
| Article | Year |
|---|---|
Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hearing Loss; Hyperglycemia; La | 2015 |